BioCatalyst

NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab — catalyst calendar

1 verified catalyst event(s) referencing NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, each linked to its official source. Verified as of 2026-10-28.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-02-28
in 4mo
ESTIMATED
 READOUT
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblast
Phase 1/2 · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
 NTHI NEONC TECHNOLOGIES HOLDINGS, NEO212 Oral Capsule, Ipilimumab, Pembrol ClinicalTrials.gov ↗
✓ Source-checked 2026-10-28
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.